Sotatercept for Japanese Children With Pulmonary Arterial Hypertension
Treatments studied
Part of Lungs & breathing clinical trials.
This study tests a new medicine called sotatercept in Japanese children who have pulmonary arterial hypertension (PAH)—a condition where blood vessels in the lungs become narrow and stiff, making it harder for the heart to pump blood through them. The medicine may help improve how well their hearts and lungs work together.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have pulmonary arterial hypertension (PAH) confirmed by a heart catheterization test (a tube inserted into the heart to measure blood pressure in the lung vessels)
- Your PAH must be one of these types: idiopathic (no known cause), inherited from family, caused by drugs/toxins, linked to connective tissue disease, associated with repaired congenital heart disease, or PAH with a heart shunt
- You must be in World Health Organization Functional Class I or symptomatic Class II–IV (meaning you have at least some symptoms like shortness of breath or fatigue)
- You must have been on stable PAH treatment for at least 90 days before joining the study
- You must be of Japanese nationality
- You cannot have had recent heart surgery (atrial septostomy) within the last 6 months, and certain heart defects must not be present
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests sotatercept, a medicine that targets the blood-vessel changes in pulmonary arterial hypertension (PAH), in children. It may help improve how well the heart and lungs work by changing the underlying disease process.
This study tests a new treatment called sotatercept for people with pulmonary arterial hypertension (PAH), a condition where the blood vessels in the lungs are narrow, making the heart work harder. The goal is to see if this medicine can help improve symptoms and daily function.
This study tests a medicine called sotatercept to see if it can improve how the right side of your heart pumps in people with PAH. It may help you feel better and slow down the disease.
This study tests whether people with pulmonary arterial hypertension (PAH), a type of high blood pressure in the lungs, can safely stop taking the medication sotatercept after being on it for at least 6 months and doing well. It aims to see if those who stop can maintain their health without the drug.
This trial uses a special imaging technique (xenon MRI) to see how well the lungs are functioning in people with pulmonary arterial hypertension (PAH) who are being treated with the drug sotatercept. It aims to understand if the drug improves lung function.
This study tests a new medicine called IKT-001 for people with pulmonary arterial hypertension (PAH). It aims to see if IKT-001 helps improve exercise ability and other symptoms when added to current PAH therapies.
Hear when a new Pulmonary Arterial Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.